USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: SHIFA BIOMEDICAL
City: MALVERN
State: PA
Zip+4: -
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,504,831.00 9
SBIR Phase II $2,876,291.00 2

Award List:

Search for Anti-Androgen Compounds to Overcome Resistance of Current Drugs

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Sherin S. Abdelmeguid
Award Amount: $241,752.00
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this work is to develop new prostate cancer drugs that overcome the resistance seen with current marketed anti-androgen drugs (androgens are male sex hormones). The specific aim of the proposed work is to identify novel lead compounds that… More

Search for Antithrombotic Compounds to Overcome Adverse Effects of Current Drugs

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $256,345.00
Abstract:
DESCRIPTION (provided by applicant): Uncontrolled blood clotting or thrombosis is a primary cause of death in the US and developed world. Fatal or debilitating blood clots occur in the three major diseases of the western world: heart attacks, stroke and ca ncer. Two of the major drugs used… More

Dynamic, Structure Driven Fragment Based Design of Selective Androgen Modulators

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $284,480.00
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this work is to develop novel drugs, targeted to the treatment of advanced prostate cancer, which overcome the ability of all prostate cancers to evolve resistance to current antiandrogen drugs. Th ese changes lead to a poor prognosis and… More

Structure-Based Search for Novel Antihypercholestrolemic Agents

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $258,966.00
Abstract:
DESCRIPTION (provided by applicant): Heart disease is the leading cause of death for both men and women in the US, accounting for nearly 40% of all annual deaths. A high cholesterol level is a well-known risk factors for heart disease. Although blood chole sterol can be lowered using a number of… More

Novel Modulators of LDL Metabolism

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Nabil A. Elshourbagy
Award Amount: $258,591.00
Abstract:
DESCRIPTION (provided by applicant): Heart disease is the leading cause of death for both men and women in the US, accounting for nearly 40% of all annual deaths. A high cholesterol level is a well-known risk factor for heart disease. Although blood choles terol can be lowered using a number of… More

Novel Modulators of HDL Metabolism

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Nabil A. Elshourbagy
Award Amount: $270,518.00
Abstract:
DESCRIPTION (provided by applicant): Cardiovascular disease remains the leading cause of morbidity and mortality for both men and women, accounting for nearly 40% of annual deaths. High levels of low-density lipoprotein cholesterol (LDL-C) and low level of high-density lipoprotein cholesterol… More

Structure-Based Search for Novel Antihypercholestrolemic Agent

Award Year / Program / Phase: 2010 / SBIR / Phase II
Agency: HHS
Principal Investigator: Sherin S. Abdelmeguid
Award Amount: $1,336,676.00
Abstract:
DESCRIPTION (provided by applicant): Heart disease is the leading cause of death for both men and women in the US, accounting for nearly 40% of all annual deaths. A high cholesterol level is well-known risk factors for heart disease. Although blood cholest erol can be lowered using a number of… More

Structure-Based Design of Novel HNF4a Antagonists to Treat Metabolic Syndrome

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Arnold T. Hagler
Award Amount: $290,230.00
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this work is to develop novel drugs for the treatment of metabolic syndrome (MetS). MetS is an assemblage of associated clinical disorders recognized only some 20 years ago to be linked. They inclu de insulin resistance, hypertension,… More

Novel Modulators of HDL Metabolism

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: Nabil A. Elshourbagy – 610-400-1243
Award Amount: $1,539,615.00
Abstract:
Project Summary/Abstract Cardiovascular disease remains the leading cause of morbidity and mortality for both men and women, accounting for nearly 40% of annual deaths. High levels of LDL-C and low levels of HDL-C are well-known risk factors for heart disease. Although lowering low-density… More

A Novel Cassette System for the Assembly of VLP Vaccines

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michael N. Blackburn – 610-400-1243
Award Amount: $296,731.00
Abstract:
DESCRIPTION (provided by applicant): Influenza and other infectious diseases are a major cause of death in the US and world-wide. Vaccination is the most cost-effective strategy to prevent these diseases. Although much progress has been made in vaccine technology, the timely design, validation and… More

Novel Self-Limiting Prothrombinase Inhibitors

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michael N. Blackburn – 610-400-1243
Award Amount: $347,218.00
Abstract:
Project Summary/Abstract Thrombosis is a primary cause of death in the US and developed world. Fatal or debilitating blood clots occur in the three major diseases of the western world: heart attacks, stroke and cancer. Two of the major drugs used therapeutically to prevent blood clots are in the… More